Sui-Whi Jane1,2,3,4, Shu-Ching Chen5,6,7,8, Ting-Yu Chiang9, Hung-Chih Hsu10,11. 1. School of Nursing, College of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan. 2. Division of Hematology/Oncology, Department of Internal Medicine, Linkou Chang Gung Memorial Hospital, Taoyuan, Taiwan. 3. School of Nursing, College of Medicine, Chang Gung University, Taoyuan, Taiwan. 4. Geriatric and Long-Term Care Research Center, College of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan. 5. School of Nursing, College of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan. shuching@gw.cgust.edu.tw. 6. School of Nursing, College of Medicine, Chang Gung University, Taoyuan, Taiwan. shuching@gw.cgust.edu.tw. 7. Geriatric and Long-Term Care Research Center, College of Nursing, Chang Gung University of Science and Technology, Taoyuan, Taiwan. shuching@gw.cgust.edu.tw. 8. Department of Radiation Oncology and Proton and Radiation Therapy Center, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. shuching@gw.cgust.edu.tw. 9. Department of Nursing, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. 10. Division of Hematology/Oncology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan. 11. College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Abstract
PURPOSE: The purposes of this study were to assess the levels of symptom distress, body image, and epidermal growth factor receptor inhibitors (EGFRI)-associated health-related quality of life (QoL); identify the factors related to EGFRI-associated health-related QoL; and examine the differences in EGFRI-associated health-related QoL by grade of skin toxicity in mCRC patients receiving target therapy. METHODS: This cross-sectional study examined mCRC patients who received cetuximab-based target therapy from the oncology and CRC inpatient and outpatient departments of a medical center in northern Taiwan. Structured questionnaires were used to measure patients' symptom distress, body image, and EGFRI-associated health-related QoL. RESULTS: Of the 111 mCRC patients studied, 79.2% reported acneiform eruption and 52.2% reported paronychia. The most common symptoms were dry skin and itching. Poor EGFRI-associated health-related QoL was associated with more symptom distress, more negative body image, a higher cumulative dose of target therapy, and being married; these factors explained 66.6% of the variance in EGFRI-associated health-related QoL. CONCLUSION: Patient-specific skin care and emotional support are needed to relieve distressful dermatological symptoms and emotional distress during and post-treatment for mCRC.
PURPOSE: The purposes of this study were to assess the levels of symptom distress, body image, and epidermal growth factor receptor inhibitors (EGFRI)-associated health-related quality of life (QoL); identify the factors related to EGFRI-associated health-related QoL; and examine the differences in EGFRI-associated health-related QoL by grade of skin toxicity in mCRC patients receiving target therapy. METHODS: This cross-sectional study examined mCRC patients who received cetuximab-based target therapy from the oncology and CRC inpatient and outpatient departments of a medical center in northern Taiwan. Structured questionnaires were used to measure patients' symptom distress, body image, and EGFRI-associated health-related QoL. RESULTS: Of the 111 mCRC patients studied, 79.2% reported acneiform eruption and 52.2% reported paronychia. The most common symptoms were dry skin and itching. Poor EGFRI-associated health-related QoL was associated with more symptom distress, more negative body image, a higher cumulative dose of target therapy, and being married; these factors explained 66.6% of the variance in EGFRI-associated health-related QoL. CONCLUSION:Patient-specific skin care and emotional support are needed to relieve distressful dermatological symptoms and emotional distress during and post-treatment for mCRC.
Entities:
Keywords:
Body image; Cetuximab; Colorectal cancer; Health-related quality of life; Molecular targeted therapy; Skin toxic
Authors: Lynne I Wagner; Sara R Berg; Mona Gandhi; Fay J Hlubocky; Kimberly Webster; Monika Aneja; David Cella; Mario E Lacouture Journal: Support Care Cancer Date: 2012-11-07 Impact factor: 3.603
Authors: Hsing-Wei Hung; Chien-Ying Liu; Hsiu-Fang Chen; Chun-Chu Chang; Shu-Ching Chen Journal: Int J Environ Res Public Health Date: 2021-05-26 Impact factor: 3.390